May 25, 2024, 10:20
An ASCO 24 Educational Session will review accelerated approval of lifileucel in advanced melanoma
ASCO (American Society of Clinical Oncology) shared on X:
“Accelerated approval of lifileucel in advanced melanoma is first T-cell Treatment approved for solid tumors.
An ASCO24 Educational Session will review supporting evidence, discuss practical considerations for clinic use, and more.”
Source: ASCO/X
The American Society of Clinical Oncology (ASCO) is a leading professional organization representing nearly 45,000 physicians and oncology specialists worldwide, dedicated to cancer care.
Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, ASCO is committed to advancing cancer research, education, prevention, and high-quality patient care.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 20, 2024, 13:52
Nov 20, 2024, 13:49
Nov 20, 2024, 13:45
Nov 20, 2024, 13:36
Nov 20, 2024, 13:34
Nov 20, 2024, 13:28
Nov 20, 2024, 13:26